Raymond James Maintains Outperform on Cytokinetics, Lowers Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Sean McCutcheon maintains an Outperform rating on Cytokinetics (NASDAQ:CYTK) but lowers the price target from $92 to $70.
May 23, 2024 | 2:26 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Raymond James has maintained its Outperform rating on Cytokinetics but has lowered the price target from $92 to $70, indicating a more cautious outlook.
The Outperform rating suggests continued confidence in the company's performance, but the lowered price target indicates a more cautious outlook, which could lead to mixed investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100